---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-149623"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2026-04-09T23:59:59+00:00"
generated_at: "2026-05-15T06:45:39.286901+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology appoints permanent CEO, new CFO and COO; Muntner gets stock option inducement

## Summary
- Mani Mohindru promoted from interim to President & CEO; base salary $655K, $100K bonus plus 55% discretionary.
- Josh Muntner named CFO effective April 6, 2026; base salary $475K, 40% bonus; granted options to buy 486,650 shares at $1.58.
- Ajay Aggarwal appointed COO effective April 27, 2026; base salary $490K, 40% bonus; expects 400,000 stock options.
- Muntner has 25+ years biopharma finance experience, previously CFO at Imvax and Mesoblast, raised over $300M combined.
- Dr. Aggarwal brings 15+ years pharma experience, most recently SVP Clinical Development at Aclaris Therapeutics.

## SEC filing metadata
- accession: 0001193125-26-149623
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2026-04-09T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000119312526149623/0001193125-26-149623-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000119312526149623/crdf-20260406.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-149623
- JSON: https://secwatch.observer/filing/0001193125-26-149623.json
- Plain text: https://secwatch.observer/filing/0001193125-26-149623.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.